Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) EVP Stephen P. Robertson sold 19,402 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total value of $173,453.88. Following the completion of the sale, the executive vice president now owns 303,364 shares in the company, valued at $2,712,074.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Aurinia Pharmaceuticals Stock Performance
NASDAQ:AUPH opened at $9.17 on Tuesday. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.07 and a 52-week high of $13.41. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -12.07 and a beta of 1.16. The business’s fifty day moving average is $7.98 and its 200 day moving average is $6.95.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 25.44% and a negative net margin of 80.71%. The company had revenue of $28.40 million for the quarter, compared to analyst estimates of $28.82 million. During the same period in the previous year, the company posted ($0.25) EPS. The firm’s revenue for the quarter was up 21.4% compared to the same quarter last year. Equities analysts predict that Aurinia Pharmaceuticals Inc. will post -0.5 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Aurinia Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its stake in Aurinia Pharmaceuticals by 590.6% in the 4th quarter. Armistice Capital LLC now owns 5,000,000 shares of the biotechnology company’s stock worth $21,600,000 after acquiring an additional 4,276,000 shares during the last quarter. Bellevue Group AG increased its stake in Aurinia Pharmaceuticals by 6.6% in the 3rd quarter. Bellevue Group AG now owns 2,846,457 shares of the biotechnology company’s stock worth $21,405,000 after acquiring an additional 175,044 shares during the last quarter. State Street Corp increased its stake in Aurinia Pharmaceuticals by 2.2% in the 3rd quarter. State Street Corp now owns 2,441,434 shares of the biotechnology company’s stock worth $18,360,000 after acquiring an additional 53,572 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Aurinia Pharmaceuticals in the 4th quarter worth about $9,431,000. Finally, BlackRock Inc. increased its stake in Aurinia Pharmaceuticals by 0.4% in the 1st quarter. BlackRock Inc. now owns 1,827,416 shares of the biotechnology company’s stock worth $22,624,000 after acquiring an additional 6,677 shares during the last quarter. 40.36% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.